Ranbaxy Laboratory (Q, N,C,F)* Ltd and other pharmaceutical companies are likely to reach an agreement by next month that will allow them to set up units within the `product-specific` pharmaceutical SEZ at Mohali, reports Business Standard. The pharma SEZ, spread over 80 acres in Mohali`s Industrial Estate in sector 76, is expected to emerge as a preferred destination for export-oriented pharma industries and R&D facilities. An investment of Rs 300 crore will be made in it over the next four years. The proposed facility will be the largest manufacturing site for formulations and the `future of Ranbaxy`, catering to the international market. Ranbaxy, one of India`s largest pharmaceutical companies, already has a production unit in Mohali. With the addition of a capsule division here, Ranbaxy will manufacture solid oral dose-like tablets and capsules.
Posted By Staff Reporter
in Punjab News
0 comments